SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Us2.ai Partners with Leading Academic Medical Center to Collaborate on AI-Enabled Echocardiography Software
SINGAPORE--September 13, 2023--Us2.ai, a Singapore-based MedTech firm, has partnered with Duke University to co-develop and commercialize AI tools for echocardiography, to enable earlier detection, improved diagnosis and more efficient management of heart disease.
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.